

#54354

Date: March 22, 2024

Subject: Homology Medicines, Inc. - Reverse Split and

Name/Symbol/CUSIP Change

Option Symbol: FIXX New Symbol: QTTB1 Date: 03/26/2024

Homology Medicines, Inc. (FIXX) has announced a 1-for-18 reverse stock split and name, symbol, and CUSIP change in conjunction with a business combination with Q32 Bio Inc. As a result of the reverse stock split, each FIXX Common Share will be converted into the right to receive approximately 0.055556 (New) Q32 Bio Inc. Common Shares. The reverse stock split and underlying changes will become effective before the market open on March 26, 2024. Cash will be paid in lieu of fractional shares.

NOTE: FIXX will also grant one non-transferrable Contingent Value Right (CVR) per FIXX share to premerger shareholders as of the March 21, 2024 record date. The CVR represents a non-transferable contractual right to receive additional payments, as described in the FIXX/QTTB Proxy Statement/Prospectus dated February 14, 2024.

Exercise Consideration - FIXX options will **not** be adjusted to call for the delivery of the non-transferable CVRs. Call holders who wish to ensure entitlement to the Contingent Value Rights must exercise their options in sufficient time to become a holder of record to receive the non-transferable CVRs. In all cases, it is the sole responsibility of persons holding call options seeking entitlement to the non-transferable CVRs to determine when to exercise their options.

Contract Adjustment

Effective Date: March 26, 2024

Option Symbol: FIXX changes to QTTB1

1

Contract

Multiplier:

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable

Per Contract: 1) 5 (New) Q32 Bio Inc. (QTTB) Common Shares

2) Cash in lieu of approximately 0.5556 fractional QTTB Shares

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

CUSIP: QTTB (New): 746964105

Pricing

Until the cash in lieu amount is determined, the underlying price for QTTB1 will be determined as follows:

QTTB1 = 0.055556 (QTTB)

Delayed Settlement

The QTTB component of the QTTB1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the QTTB1 deliverable until the cash in lieu of fractional QTTB Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.